Please login to the form below

Not currently logged in
Email:
Password:

PD-1 inhibitor

This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival. ... By attaching to PD-1, Opdivo blocks its action and allows the body’s immune system to continue to attack the gastric, oesophageal or gastro-oesophageal

Latest news

More from news
Approximately 7 fully matching, plus 292 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Pharma deals in September 2015 Pharma deals in September 2015

    taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...